Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ
Tải xuống
Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học Radiation Oncology cung cấp cho các bạn kiến thức về ngành y đề tài: RadioImmunotherapy for adenoid cystic carcinoma: a single-institution series of combined treatment with cetuximab. | Jensen et al. Radiation Oncology 2010 5 102 http www.ro-journal.eom content 5 1 102 RESEARCH RADIATION ONCOLOGY Open Access Radioimmunotherapy for adenoid cystic carcinoma a single-institution series of combined treatment with cetuximab 1 2 3 1 1 Alexandra D Jensen Jurgen Krauss Wilko Weichert Jurgen Debus Marc W Munter Abstract Background Local control in adjuvant definitive RT of adenoid cystic carcinoma ACC is largely dose-dependent. However some clinical situations do not allow application of tumouricidal doses i.e. re-irradiation hence radiation sensitization by exploitation of high endothelial growth factor receptor EGFR -expression in ACC seems beneficial. This is a single-institution experience of combined radioimmunotherapy RIT with the EGFR-inhibitor cetuximab. Methods Between 2006 and 2010 9 pts received RIT for advanced recurrent ACC 5 9 pts as re-irradiation. Baseline characteristics as well as treatment parameters were retrieved to evaluate efficacy and toxicity of the combination regimen were evaluated. Control rates local distant and overall survival were calculated using Kaplan-Meier estimation. Results Median dose was 65 Gy pts received a median of 6 cycles cetuximab. RIT was tolerated well with only one III mucositis dysphagia. Overall response remission rates were high 77 8 2-year estimate of local control was 80 hence reaching local control levels comparable to high-dose RT. Progression-free survival PFS at 2 years and median overall survival were only 62 5 and 22 2 mo respectively. Conclusion While local control and treatment response in RIT seems promising PFS and overall survival are still hampered by distant failure. The potential benefit of RIT with cetuximab warrants exploration in a prospective controlled clinical trial. Introduction Adenoid cystic carcinomas are rare tumours mostly of the head and neck and account for approximately 10-15 of malignant salivary gland tumours 1 . They are characterised by a rather slow growth pattern but .
